OncoMatch/Clinical Trials/NCT06952920
Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer
Is NCT06952920 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including electroacupuncture and standard quadruple antiemetic therapy for standard quadruple antiemetic therapy.
Treatment: electroacupuncture · standard quadruple antiemetic therapy · sham electroacupuncture — This study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects and underlying mechanisms of electroacupuncture on gastrointestinal symptoms. Ultimately, genomic studies will be performed to further clarify the key targets of electroacupuncture intervention, thereby providing high-level evidence-based medical support and theoretical foundations for optimizing electroacupuncture strategies in addressing chemotherapy-induced gastrointestinal symptoms in patients with cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Required: Stage I, II, III
Excluded: Stage ADVANCED-STAGE CANCER
stage I-III breast cancer; Patients with advanced-stage cancer [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
adequate bone marrow function as defined by standard laboratory criteria
Kidney function
adequate kidney function as defined by standard laboratory criteria
Liver function
adequate liver function as defined by standard laboratory criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06952920 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages